Longer-term safety and efficacy of ofatumumab in recently diagnosed and treatment naive patients is consistent with the overall population in the ALITHIOS open-label extension study

被引：0

作者：

Ashgari, Rozhin ^{[1
]}

Gaertner, Jutta ^{[2
]}

Hauser, Stephen ^{[3
]}

Bar-Or, Amit ^{[4
,5
]}

Montalban, Xavier ^{[6
]}

Cohen, Jeffrey ^{[7
]}

Robertson, Derrick ^{[8
]}

Cross, Anne ^{[9
]}

Hersh, Carrie ^{[10
]}

Deiva, Kumaran ^{[11
]}

Goeri, Karlsson ^{[12
]}

Das Gupta, Ayan ^{[13
]}

Zielman, Ronald ^{[14
]}

Ansari, Soudeh ^{[15
]}

Kieseier, Bernd ^{[12
]}

Kappos, Ludwig ^{[16
,17
,18
,19
,20
,21
]}

机构：

[1] Novartis Pharmaceut Australia, Macquarie Pk, Australia

[2] Georg August Univ Gottingen, Univ Med Ctr Gottingen, Div Paediat Neurol, Dept Paediat & Adolescent Med, Gottingen, Germany

[3] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA USA

[4] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Perelman Sch Med, Philadelphia, PA USA

[5] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA USA

[6] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

[7] Cleveland Clin, Neurol Inst, Dept Neurol, Mellen MS Ctr, Cleveland, OH USA

[8] Univ S Florida, Multiple Sclerosis Div, Dept Neurol, Tampa, FL USA

[9] Washington Univ, Dept Neurol, Sch Med, Sect Neuroimmunol, St Louis, MO USA

[10] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA

[11] Hop Bicetre, Univ Hosp Paris Saclay, Dept Pediat Neurol, Natl Reference Ctr Rare Inflammatory Brain & Spin, Le Kremlin Bicetre, France

[12] Novartis Pharma AG, Basel, Switzerland

[13] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India

[14] Novartis Pharma BV, Amsterdam, Netherlands

[15] Novartis Inst Biomed, Cambridge, MA USA

[16] Univ Hosp, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland

[17] Univ Hosp, MS Ctr, Dept Head Spine & Neuromed, Basel, Switzerland

[18] Univ Hosp, MS Ctr, Dept Clin Res, Basel, Switzerland

[19] Univ Hosp, MS Ctr, Dept Biomed, Basel, Switzerland

[20] Univ Hosp, MS Ctr, Dept Biomed Engn, Basel, Switzerland

[21] Univ Basel, Basel, Switzerland

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-60

引用

页码：NP33 / NP34

页数：2

共 50 条

[1] Longer-term safety and efficacy of ofatumumab in recently diagnosed and treatment naive patients is consistent with the overall population in the ALITHIOS open-label extension study
Gaertner, J.
Hauser, S. L.
Bar-Or, A.
Montalban, X.
Cohen, J. A.
Robertson, D.
Cross, A. H.
Hersh, C. M.
Deiva, K.
Goeril, K.
Gupta, A. D.
Zielman, R.
Ansari, S.
Kieseier, B.
Kappos, L.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 167 - 168
[2] Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
Hauser, Stephen L.
Zielman, Ronald
Das Gupta, Ayan
Xi, Jing
Stoneman, Dee
Karlsson, Goeril
Robertson, Derrick
Cohen, Jeffrey A.
Kappos, Ludwig
[J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (11-12) : 1452 - 1464
[3] Five-Year Efficacy Outcomes of Ofatumumab in Relapsing MS Patients: Insights From ALITHIOS Open-label Extension Study
Kappos, L.
Cohen, J.
Gold, R.
De Seze, J.
Robertson, D.
Wiendl, H.
Wray, S.
Zielman, R.
Azmon, A.
Xi, J.
Boer, I.
Hauser, S.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 185 - 186
[4] Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, Hitoshi
Dording, Christina
Yeung, Albert
Foster, Simmie
Jain, Felipe
Chang, Trina
Trinh, Nhi-Ha
Bernard, Richard
Boyden, Sean
Iqbal, Syed Z.
Wilkinson, Samuel T.
Mathew, Sanjay J.
Mischoulon, David
Fava, Maurizio
Cusin, Cristina
[J]. JOURNAL OF AFFECTIVE DISORDERS, 2019, 258 : 102 - 108
[5] Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
Gaertner, Jutta
Hauser, Stephen L.
Bar-Or, Amit
Montalban, Xavier
Cohen, Jeffrey A.
Cross, Anne H.
Deiva, Kumaran
Ganjgahi, Habib
Haering, Dieter A.
Li, Bingbing
Pingili, Ratnakar
Ramanathan, Krishnan
Su, Wendy
Willi, Roman
Kieseier, Bernd
Kappos, Ludwig
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (10) : 1562 - 1575
[6] Consistent efficacy and safety of erenumab in episodic migraine patients during a 5-year, open-label extension study
Ashina, M.
Goadsby, P.
Reuter, U.
Silberstein, S.
Dodick, D.
Zhang, F.
Xue, F.
Cheng, S.
Chou, D.
Lima, G. Paiva da Silva
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 153 - 154
[7] Nusinersen in Infantile-onset Spinal Muscular Atrophy: Results from Longer-term Treatment from the Open-label SHINE Extension Study
Castro, Diana
Finkel, Richard S.
Farrar, Michelle A.
Tulinius, Mar
Krosschell, Kristin J.
Saito, Kayoko
Gambino, Giulia
Foster, Richard
Bhan, Ishir
Wong, Janice
Kandinov, Boris
Farwell, Wildon
[J]. NEUROLOGY, 2020, 94 (15)
[8] Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study
Finkel, R.
Castro, D.
Farrar, M.
Tulinius, M.
Krosschell, K.
Saito, K.
Gambino, G.
Foster, R.
Ramirez-Schrempp, D.
Wong, J.
Kandinov, B.
Farwell, W.
[J]. NEUROMUSCULAR DISORDERS, 2020, 30 : S124 - S124
[9] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
Feist, Eugen
Nasonov, Evgeny
Luggen, Michael
Fatenejad, Saeed
Grishin, Sergey
Samsonov, Mikhail
Fleischmann, Roy
[J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
[10] Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
Gevaert, Philippe
Saenz, Rebecca
Corren, Jonathan
Han, Joseph K.
Mullol, Joaquim
Lee, Stella E.
Ow, Randall A.
Zhao, Rui
Howard, Monet
Wong, Kit
Islam, Lutaf
Ligueros-Saylan, Monica
Omachi, Theodore A.
Bachert, Claus
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 957 - +

← 1 2 3 4 5 →